Pharmacogenomics: the key to improved drug therapy in transplant patients.
The current success in organ transplantation has been brought about by immunosuppressive therapy. Improvements in transplant outcome using these drugs have stalled, and an understanding of the pharmacogenomics of immunosuppressive dosing and response holds the greatest promise for advancing the use of these agents.
Burckart
Gilbert J
GJ
Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Building 51, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA. gilbert.burckart@fda.hhs.gov
D054316:Biomarkers, Pharmacological; D006084:Graft Rejection / Q000188:drug therapy / Q000235:genetics* / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D018448:Models, Immunological; D015166:Monitoring, Immunologic; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D011506:Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D016896:Treatment Outcome
D054316:Biomarkers, Pharmacological; D007166:Immunosuppressive Agents; D011506:Proteins